A phase I dose-escalation study of Lobaplatin combined with paclitaxel in platinum-sensitive recurrent ovarian epithelial carcinoma: preliminary safety and tolerability supporting clinical trial dosing
{{output}}
Objective: To establish the recommended dose (MTD) and assess the safety and tolerability of lobaplatin (LBP) combined with paclitaxel for subsequent clinical development in platinum-sensitive recurrent ovarian epithelial carcinoma (PSROC), with antitumor acti... ...
